肝癌患者外周血树突状细胞免疫功能的研究

目的 研究树突状细胞(DC)表面免疫分子HLA-DR及B2表达水平及其与DC免疫诱导能力相关性.并进一步探讨DC免疫功能在宿主免疫功能中的作用。方法 以健康成人(n=10)作为对照．检测临床确诊肝癌患(n=10)外周血DC表面免疫分子HLA-DR及B，表达水平及DC免疫诱导能力．结果 肝癌患DC表面HLADR及B2表达水平(6.7±1.6及6.1±1.1)明显低于对照组(10.7±1.4及9.6±1.2VOF,P<0.05).其DC体外诱导T细胞增殖能力(3100±120cpm)亦明显低于对照组(6200±90cpm,P<0.01)：以抗HLA-DR单抗及抗B2单抗完全封闭对照组DC表面HLA-DR及B2．则该DC诱导T细胞增殖能力(3900±1.5cpm)亦明显低于对照组(6200±90cpm．P<0.05)．结论 肝癌患DC表面HLA-DR及B2表达水平下降与DC免疫功能低下密切相关，DC免疫功能低下可能是肝癌(或许包括其它肿瘤)逃避宿主免疫监视的重要原因。     

体外诱导人骨髓单个核细胞生成树突状细胞的实验研究

目的通过体外诱导人骨髓单个核细胞（MNC）生成大量树突状细胞（DC）,为抗肿瘤免疫提供效应细胞。方法使用淋巴细胞分层液密度梯度离心技术从人骨髓中分离大量的MNC,利用几种细胞因子GM-CSF、TNF-a、SCF、FL进行配伍的方法诱导MNC生成DC,利用光镜和电镜观察细胞形态并用流式细胞仪检测细胞表型。结果MNC经细胞因子组合诱导后定向分化为DC,DC由未成熟状态过渡到成熟状态,DC细胞表型发生改变。结论经细胞因子配伍可诱导MNC生成大量DC。     

树突状细胞诱导抗胃癌移植瘤免疫

目的　研究树突状细胞 (DC)体外诱导的抗肿瘤免疫能否抑制裸鼠移植瘤生长并预防其发生。方法　联合应用粒 /巨噬细胞集落刺激因子 (GM -CSF)及白介素 4(IL 4)直接从胃癌患者外周血中培养出DC ;以SGC -790 1细胞的肿瘤抗原粗提物刺激DC使其激活同源的T淋巴细胞产生细胞毒性T淋巴细胞 (CTL) ;建立裸鼠SGC -790 1细胞移植瘤模型 ;DC诱导的CTL治疗裸鼠SGC -790 1细胞移植瘤 ,观察移植瘤生长 ;DC诱导的CTL预防性治疗裸鼠 ,观察随后接种的SGC -790 1细胞移植瘤发生情况。结果　DC诱导的CTL不仅能抑制裸鼠移植瘤生长并能预防其发生。结论　经肿瘤抗原激活的DC作为一新概念上的抗肿瘤疫苗有可能在治疗肿瘤及预防其术后复发和转移中发挥重要作用。     

肝癌树突状细胞疫苗诱导细胞毒性T淋巴细胞的效应

肝癌患者体内的树突状细胞(DC)负载肝癌相关抗原，诱导机体产生有效的免疫应答，是肝癌治疗的一条有效途径。     

非淋巴细胞白血病原代细胞诱导成树突状细胞的研究

目的：用白血病细胞诱导树突状细胞,为白血病的免疫治疗提供新途径。方法：分离人的非淋巴细胞白血病原代细胞,体外流体培养体系中加入ＧＭ－ＣＳＦ、ＴＮＦ－α及ＩＬ－４,培养１２ｄ后,与培养前的细胞在形态、ＣＤ１ａ、ＨＬＡ－ＤＲ及ＣＤ８０的表达情况进行比较。结果：经１２ｄ诱导,细胞形态表现典型的树突状细胞的特征;ＣＤ１ａ、ＨＬＡ－ＤＲ及ＣＤ８０的表达明显增高。结论：可将非淋巴细胞白血病原代细胞诱导成树突状     

Ghrelin增强树突状细胞的免疫功能

目的 探讨Ghrelin能否调节树突状细胞(DC)的免疫功能.方法 自人外周血单核细胞制备DC;以TNF-α诱导DC成熟,然后以Ghrelin刺激DC;检测经Ghrelin刺激后DC表面B7-H1的表达和细胞因子的表达,并进一步检测该DC诱导T淋巴细胞增值能力.结果 Ghrelin下调TNF-a诱导的B7H1的表达,并进一步增强其诱导T淋巴细胞增殖活性;抗B7-H1抗体能增强该DC诱导T淋巴细胞增值活性;特异性的PKC抑制剂能逆转Ghrelin对DC免疫功能的调节.结论 Ghrelin通过抑制B7-H1表达增强DC的免疫功能,提示Ghrelin将可能在肿瘤和感染性疾病中发挥重要作用.     

树突状细胞与移植免疫

树突状细胞(dendriticcell,DC)是体内最重要的抗原提呈细胞(antigenpresentcell,APC) ,其免疫学功能具有两重性,既可介导免疫激活,也可介导免疫耐受。随着新型免疫抑制剂的诞生,肝移植术后移植物的急性排斥现象明显减少,但其非选择性的广泛免疫抑制作用,以及药物本身的不良反应仍具有一定的危害性。利用DC的免疫调节作用,诱导免疫耐受是当前移植领域的研究热点之一。一、DC的免疫学(一)DC的分型及发育　DC分布于除脑以外的全身各脏器。根据不同起源将小鼠DC分为髓系DC(myeloidderivedsub set,MDC)和淋巴系DC(lymphoidderivedsubset…     

树突状细胞联合细胞因子诱导的杀伤细胞抗肿瘤效应研究

树突状细胞(DC)与细胞因子诱导的杀伤细胞(CIK)是肿瘤免疫治疗的两个重要部分,DC是人体内专职抗原递呈细胞,CIK是高效肿瘤杀伤细胞,前者识别病原,启动获得性免疫系统,后者通过发挥自身细胞毒性与分泌性细胞因子杀伤肿瘤,两者联合可以更好的杀伤肿瘤细胞,被认为是肿瘤过继免疫治疗的新希望。     

Probiotic Bio-Three induces Th1 and anti-inflammatory effects in PBMC and dendritic cells

AIM:To investigate the immune response of peripheral blood mononuclear cells(PBMCs)and dendritic cells (DCs)that were stimulated by probiotic preparations. METHODS:PBMCs were isolated,cultured,and stimulated with Bio-Three(a mixture of Bacillus mesentericus, Clostridium butyricum and Enterococcus faecalis;105, 10 6 and 10 7 CFU/mL for 24 h).Cytokine production of (1)circulating PBMCs;(2)PBMCs stimulated by probiotic preparation;(3)monocyte-derived DCs;and(4)DC andT cell co-culture was determined by enzyme-l...     

慢性乙型肝炎患者树突状细胞功能与单个核细胞乙型肝炎病毒共价闭合环状DNA的关系

目的 探讨慢性乙型肝炎(CHB)患者外周血单个核细胞(PBMC)及树突状细胞(DC)内HBV共价闭合环状DNA(HBV cccDNA)的存在状况,DC成熟度及功能状态与DC或PBMC中HBV cccDNA载量的关系.方法 分离29例CHB患者和10例健康对照者的PBMC,用重组人粒细胞-巨噬细胞集落刺激因子(GM-CS...     

Effects of dendritic cells from cord blood CD34^＋ cells on human hepatocarcinoma cell line BEL-7402 in vitro and in SCID mice

AIM: To develop a cancer vaccine of dendritic cells derived from human cord blood CD34+ cells and to investigate its cytotoxicity on human hepatocarcinoma cells in vitro and in sever combined immunodeficiency (SCID) mice. METHODS: Lymphocytes from cord blood or peripheral blood were primed by DCs, which were derived from cord blood and pulsed with whole tumor cell lysates. Nonradiative neutral red uptake assay was adopted to detect the cytotoxicity of primed lymphocytes on human hepatocartinoma cell line BEL-7402 in vitro. The anti-tumor effect of primed lymphocytes in vivo was detected in SCID mice, including therapeutic effect and vaccination effect. RESULTS: The cytotoxicity of DC vaccine primed lymphocytes from cord blood or peripheral blood on human hepatocarcinoma cell line BEL-7402 was significantly higher than that of unprimed lymphocytes in vitro (44.09% vs 14.69%, 47.92% vs 19.44%, P<0.01). There was no significant difference between the cytotoxicity of primed lymphocytes from cord blood and peripheral blood (P>0.05). The tumor growth rate and tumor size were smaller in SCID mice treated or vaccinated with primed lymphocytes than those with unprimed lymphocytes. SCID mice vaccinated with primed lymphocytes had a lower tumor incidence (80% vs 100%, P<0.05) and delayed tumor latent period compared with mice vaccinated with unprimed lymphocytes (11d vs 7 d,P<0.01). CONCLUSION: Vaccine of cord blood derived-DCs has an inhibitory activity on growth of human hepatocarcinoma cells in vitro and in SCID mice. The results also implicate the potential role of cord blood derived-DC vaccine in clinical tumor immunotherapy.     

人脐血和外周血树突状细胞诱导抗肝癌活性

目的　观察人脐血和外周血树突状细胞 (dendriticcells ,DC)的生物学特性及其对效应细胞体外杀伤人肝癌细胞株BEL 740 2 (B)的影响。方法　免疫组化和MTT法检测DC的生物学特性。抗肿瘤实验则分两大组 ,人外周血DC组为B +LAK +DC ,人脐血DC组为B +DC CTL ,检测效应细胞的细胞毒活性。结果　①人外周血和脐血DC均高表达HLA ABC、HLA DR、HLA DQ、CD54和S 10 0蛋白 ;刺激淋巴细胞增殖的效应均比对照组明显增高 (P <0 0 1) ,两种来源DC无显著性差异 (P >0 0 5)。②人外周血DC组和脐血DC组的细胞毒活性均为实验组 >对照组 (P <0 0 1) ,人脐血DC组 >人外周血DC组 (P <0 0 1)。结论　人外周血和脐血DC均为形态和功能成熟的DC ,均能明显增强效应细胞杀伤肝癌细胞的活性 ;而经肿瘤抗原致敏DC诱导的特异性CTL杀伤活性更强。提示临床上可根据患者的具体情况选择DC的来源     

乙型肝炎患者外周血单个核细胞端粒酶活性的研究

目的 了解乙型肝炎患者外周血单个核细胞（PBMC）端粒酶活性的表达情况。方法 通过扩增端粒重复序列（TRAP）及光度酶联免疫法，分别检测健康人及各类乙型肝炎患者PBMC的端粒酶水平。结果 各组患者PBMC在植物血凝素（PHA）刺激前均有端粒酶活性的表达，以急性型肝炎组最高，重型肝炎组最低，二者差别具有显著性（P〈0．001）。PHA刺激后与刺激前比较各组端粒酶活性均有显著性升高（P〈0．001），刺激后的端粒酶水平以重型肝炎组为最低，与其他三组比较差别具有显著性（P〈0．05）。慢性重型乙型肝炎经胸腺五肽（TP5）治疗后端粒酶活性显著增高（P〈0．05）。结论 HBV急性感染期PBMC的端粒酶水平升高；慢性感染期PBMC的端粒酶水平在体内被抑制。TP5具有免疫调节作用，能使过低的端粒酶水平趋向于正常。     

慢性丙型肝炎患者外周血单个核细胞丙型肝炎病毒检测及其意义

目的 探讨外周血单个核细胞（ＰＢＭＣｓ）在丙型肝炎病毒（ＨＣＶ）的感染中的作用。方法 对２２例慢性丙型肝炎患者２１例抗－ＨＣＶ（＋）血液管析患者及１２例健康献血员的ＰＢＭＣｓ分别进行ＨＣＶＲＮＡ,ＨＣＶ抗原检测及电镜观察。结果 （１）２２生丙型肝炎肝炎患者ＰＢＭＣｓ中有７７．３％（１７／２２）ＨＣＶＲＮＡ阳性,（２）感染ＨＣＶ的ＰＢＭＣｓ中电镜下发现复制的ＨＣＶ颗粒;（３）ＨＣＶ颗粒阳笥者的血清和     

Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice

BACKGROUND: The prevention of recurrence of hepatocellular carcinoma (HCC) after treatment is very important for improvement of the prognosis of HCC patients. Dendritic cells (DCs) are potent antigen-presenting cells that can prime naive T cells to induce a primary immune response. We attempted to induce preventive antitumor immunity against HCC by immunizing BALB/c mice with fusions of DCs and HCC cells. METHODS: Murine bone marrow-derived DCs and a murine HCC cell line. BNL cells, were fused by treatment with 50% polyethyleneglvcol (PEG). Fusion efficacy was assessed by the analysis of fusions of BNL cells stained with red fluorescent dye and DCs stained with green fluorescent dye. Mice injected intravenously with DC/BNL fusions were challenged by BNL cell inoculation. RESULTS: About 30% of the PEG-treated non-adherent cells with both fluorescences were considered to be fusion cells. The cell fraction of DC/BNL fusions showed phenotypes of DCs, MHC class II, CD80, CD86, and intercellular adhesion molecule (ICAM)-1, which were not expressed on BNL cells. Mice immunized with the fusions were protected against the inoculation of BNL tumor cells, whereas injection with a mixture of DCs and BNL cells not treated with PEG did not provide significant resistance against BNL cell inoculation. Splenocytes from DC/BNL fusion-immunized mice showed lytic activity against BNL cells. CONCLUSIONS: These results demonstrate that immunization with fusions of DCs and HCC cells is capable of inducing preventive antitumor immunity against HCC.     

Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells

BACKGROUND: The response of hepatocellular carcinoma (HCC) to therapy is often disappointing and new modalities of treatment are clearly needed. Active immunotherapy based on the injection of autologous dendritic cells (DC) co-cultured ex vivo with tumor antigens has been used in pilot studies in various malignancies such as melanoma and lymphoma with encouraging results. METHODS: In the present paper, the preparation and exposure of patient DC to autologous HCC antigens and re-injection in an attempt to elicit antitumor immune responses are described. RESULTS: Therapy was given to two patients, one with hepatitis C and one with hepatitis B, who had large, multiple HCC and for whom no other therapy was available. No significant side-effects were observed. The clinical course was unchanged in one patient, who died a few months later. The other patient, whose initial prognosis was considered poor, is still alive and well more than 3 years later with evidence of slowing of tumor growth based on organ imaging. CONCLUSIONS: It is concluded that HCC may be a malignancy worthy of DC trials and sufficient details in the present paper are given for the protocol to be copied or modified.     

原位杂交法检测外周血单个核细胞中HCV RNA

目的比较慢性丙型肝炎患者用干扰素治疗前以及治疗后３个月ＰＢＭＣ中ＨＣＶＲＮＡ。方法应用地高辛素标记ＨＣＶＲＮＡ正链及负链探针，建立原位杂交方法检测外周血单个核细胞（ＰＭＢＣ）中的ＨＣＶＲＮＡ。结果治疗前１９例患者正链ＨＣＶＲＮＡ阳性，８例负链ＨＣＶＲＮＡ阳性，用正链探针杂交在较多的细胞中出现杂交信号，负链探针杂交仅在少数细胞中出现杂交信号，ＨＣＶＲＮＡ在ＰＢＭＣ胞浆中呈均质性分布。用干扰素治疗结束后３个月２０例患者中９例ＨＣＶＲＮＡ转阴性，近期治愈率４５％。结论原位杂交技术的敏感性及特异性较高，且重复性较好，是研究ＨＣＶＲＮＡ在组织中定位分布和病毒复制场所一种切实可行的方法